"A full HTA is not recommended. The NCPE recommends that lisocabtagene maraleucel not be considered for reimbursement for this indication at the submitted price." [For DLBCL, high-grade B-cell lymphoma, primary mediastinal LBCL, and grade 3B FL] (National Centre for Pharmacoeconomics, Ireland) Sep 30, 2026
HEOR • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma
|